EDITION OF MON 16 NOV 2026
160 · GENERAL

SELLAS Reports Third-Quarter Results as Tambiciclib Combination Shows AML Activity

publishers 42articles 330first reported 10 Nov, 00:15 UTCdeveloping since 12 Nov · 5 editions

SELLAS Life Sciences reported its third-quarter 2026 financial results and issued a corporate update. Separately, CancerNetwork reported that a combination involving tambiciclib showed activity in patients with relapsed or refractory acute myeloid leukemia after treatment with venetoclax.

A GuruFocus analysis of SELLAS’ quarterly filing highlighted financial challenges alongside potential for growth.

HOW THIS STORY WAS MADE

Written from 8 articles, 1 with the publisher's own text; 8 independent newsrooms once syndicated copies count as one; this version written 66 h after the record first saw the story; the editor revised it.

Publishers
42
Source articles
330
Given to the writer
8, 1 with the article's own text
Independent newsrooms
8
This version written
66 h after the record first saw the story
Second model (editor)
revised
Publication gate
passed
Human review
none

WHAT THE EDITOR DID

The second model checked the writer's draft against the same sources and changed it before publication. Struck words were in the draft; underlined words are its corrections.

WHAT IT FLAGGED editor revise: Delete the sentence commenting on what the available headlines do not disclose. - "Detailed trial results and financial figures were not disclosed in the reports’ available headlines.": This is commentary about the limits of the supplied source material rather than a reported fact.

THE DRAFT AND THE CHANGES

SELLAS Reports Third-Quarter Results as Tambiciclib Combination Shows AML Activity

SELLAS Life Sciences reported its third-quarter 2026 financial results and issued a corporate update. Separately, CancerNetwork reported that a combination involving tambiciclib showed activity in patients with relapsed or refractory acute myeloid leukemia after treatment with venetoclax. A GuruFocus analysis of SELLAS’ quarterly filing highlighted financial challenges alongside potential for growth. Detailed trial results and financial figures were not disclosed in the reports’ available headlines.

Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →

OUTLETS CARRYING THE STORY, RUN BY RUN

0 21 42 13 Nov 14 Nov 15 Nov 16 Nov 12 Nov 12:24 UTC · New Found Gold Reports Third-Quarter 2026 Results 12 Nov 18:26 UTC · Companies Announce Third-Quarter 2026 Financial Results 13 Nov 00:20 UTC · Eight Companies Announce Quarterly Financial Results 13 Nov 06:16 UTC · SELLAS Reports Quarterly Results as Leukemia Trial Analysis Approaches 13 Nov 18:19 UTC · SELLAS Life Sciences Reports Quarterly Results as Leukemia Trial Analysis Nears 14 Nov 18:25 UTC · SELLAS Reports Third-Quarter Results as Tambiciclib Combination Shows AML Activity

WHAT HELD, WHAT CAME LATER

From the first reports to the latest

  • Nothing ran from the first third of the coverage to the last.

Entered the story later

  • Nothing new took hold after the first third.

HOW THIS STORY DEVELOPED: EVERY HEADLINE, EVERY OUTLET →